Register Now: From Clinical to Commercial: Accelerating ADC Late-Stage Development with Technology Innovation and Integrated Platform
Logo Image
News|Podcasts|August 19, 2026 (Updated: August 19, 2026)

The BioPharm Brief: Cancer, Personalized

Listen
0:00 / 0:00

This week’s BioPharm Brief covers positive phase 3 melanoma results for Merck and Moderna’s individualized neoantigen therapy, a personalized cancer vaccine manufacturing platform entering clinical use, and a new brain-penetrant antibody approach for glioblastoma.

Welcome to The BioPharm Brief, your daily snapshot of developments shaping the biopharmaceutical industry.

Merck and Moderna have reported a significant phase 3 milestone for their individualized cancer vaccine approach. In the INTerpath-001 trial, intismeran autogene, also known as V940 or mRNA-4157, combined with pembrolizumab met its primary endpoint of recurrence-free survival and a key secondary endpoint of distant metastasis-free survival in patients with completely resected stage IIB to IV melanoma. The trial randomized 1,137 patients to receive either the combination or pembrolizumab alone. The companies say the result represents the first positive phase 3 readout for an individualized neoantigen therapy and an mRNA-based cancer therapy. The personalized treatment uses sequencing of a patient's tumor to identify mutations and encodes up to 34 tumor-specific neoantigens into synthetic mRNA, with the goal of generating a targeted T-cell response.

The manufacturing challenge behind personalized cancer vaccines is also moving into the clinic. NTx Bio's NTxscribe CORE platform is being used by Baylor College of Medicine to manufacture mRNA for DOC1021, a personalized double-loaded dendritic cell vaccine from Diakonos Oncology that is now being evaluated in a Phase 1 trial for refractory melanoma. The platform uses continuous-flow technology to amplify tumor-derived mRNA from small surgical biopsies while preserving the full-length range of the patient's tumor transcriptome. The approach is designed to address a major challenge in personalized cell and gene therapies, where manufacturing can be highly manual and variable. DOC1021 is also being developed for glioblastoma and pancreatic ductal adenocarcinoma.

And in glioblastoma, BioArctic and Mesenkia Therapeutics are combining two platforms to explore a new way of getting antibodies into the brain. Their research collaboration pairs BioArctic's BrainTransporter technology with a Mesenkia antibody targeting herpesvirus entry mediator, or HVEM, a protein found on certain glioblastoma tumor cells, including tumor stem cells. BrainTransporter uses transferrin receptor-mediated transport to increase antibody exposure in the brain. In preclinical work, the technology produced up to a 70-fold increase in antibody brain exposure. The companies will now generate and evaluate a candidate in preclinical studies, with further development decisions dependent on those results.

That’s The BioPharm Brief for today.

Thanks for listening. For analysis and expert insights, please visit BioPharmInternational.com.

Key takeaways:

  • Merck and Moderna reported a positive phase 3 readout for an individualized mRNA neoantigen therapy in melanoma.
  • NTx Bio's manufacturing platform is now supporting clinical production of a personalized cancer vaccine.
  • BioArctic and Mesenkia are taking a brain-delivery approach into glioblastoma research.

Related to this article

View more
The BioPharm Brief: An AI-Designed Multibody ADC Enters the Clinic, Blackstone Backs Pfizer’s Monthly GLP-1, and enGene Readies a Bladder Cancer BLA
The BioPharm Brief: An AI-Designed Multibody ADC Enters the Clinic, Blackstone Backs Pfizer’s Monthly GLP-1, and enGene Readies a Bladder Cancer BLA
FDA clears the IND for Biolojic Design’s BD200, an AI-designed Trop2/Nectin-4 multibody ADC; Blackstone Life Sciences agrees to provide Pfizer up to $1.5 billion to develop its monthly GLP-1 receptor agonist berobenatide; and enGene Therapeutics plans a year-end BLA for detalimogene voraplasmid in BCG-unresponsive non-muscle invasive bladder cancer.
Read more
The BioPharm Brief: FDA Designations for a Bispecific CAR-T, a BLA for Friedreich’s Ataxia, and Phase 2b MASH Data for Efinopegdutide
The BioPharm Brief: FDA Designations for a Bispecific CAR-T, a BLA for Friedreich’s Ataxia, and Phase 2b MASH Data for Efinopegdutide
FDA grants RMAT and Fast Track designations to AbelZeta’s CD20/CD19 bispecific CAR-T prizlon-cel in relapsed or refractory large B-cell lymphoma, Larimar Therapeutics completes a BLA seeking accelerated approval of nomlabofusp for Friedreich’s ataxia, and Merck’s GLP-1/glucagon receptor agonist efinopegdutide meets its primary endpoint in a phase 2b MASH trial.
Read more
The BioPharm Brief: argenx Bets on Peptides, a Two-Bispecific Regimen in Prostate Cancer, and a New Take on T-Cell Engagers
The BioPharm Brief: argenx Bets on Peptides, a Two-Bispecific Regimen in Prostate Cancer, and a New Take on T-Cell Engagers
argenx agrees to acquire macrocyclic peptide developer Unnatural Products for up to about $1.15 billion, Johnson & Johnson’s pasritamig and JNJ-9401 bispecific regimen achieves a 73% PSA response in phase 1 in metastatic castration-resistant prostate cancer, and Janux Therapeutics’ TRBV6-targeted T-cell engager JANX011 shows deep B-cell depletion in healthy volunteers.
Read more
The BioPharm Brief: A Bispecific Approval in Head and Neck Cancer, TCR Bispecifics Head to the Clinic, and a New Antibody Target in Essential Thrombocythemia
The BioPharm Brief: A Bispecific Approval in Head and Neck Cancer, TCR Bispecifics Head to the Clinic, and a New Antibody Target in Essential Thrombocythemia
FDA grants accelerated approval to Johnson & Johnson’s subcutaneous EGFR/MET bispecific Rybrevant Faspro for previously treated head and neck squamous cell carcinoma, T-Therapeutics raises a $133 million Series B to take TCR-CD3 bispecifics into clinical trials, and Alethio Therapeutics raises a $90 million Series A to advance its first-in-class G6B antibody for essential thrombocythemia.
Read more
The BioPharm Brief: Ivonescimab Priority Review in China, Stargardt Gene Therapy Moves Toward Phase 3, and Longer Dosing Intervals for an IBD Bispecific
The BioPharm Brief: Ivonescimab Priority Review in China, Stargardt Gene Therapy Moves Toward Phase 3, and Longer Dosing Intervals for an IBD Bispecific
China’s NMPA grants priority review to Akeso’s PD-1/VEGF bispecific ivonescimab with chemotherapy for first-line biliary tract cancer, VeonGen Therapeutics aligns with FDA on a phase 3 design for its dual-AAV Stargardt gene therapy VG801, and Caldera Therapeutics’ IL-23p19×TL1A bispecific CLD-423 shows a half-life of more than 40 days in a phase 1a trial.
Read more
The BioPharm Brief: A $7 Billion Oncology Option Deal, a TL1A Pivot, and Oral Adalimumab Heads to the Clinic
The BioPharm Brief: A $7 Billion Oncology Option Deal, a TL1A Pivot, and Oral Adalimumab Heads to the Clinic
Boehringer Ingelheim licenses six preclinical ADC and T-cell engager programs from Sino Biopharmaceutical in a deal worth up to $7 billion, Spyre Therapeutics drops anti-TL1A antibody SPY072 in rheumatic diseases after phase 2 misses and turns to hidradenitis suppurativa, and Biora Therapeutics gets ethics approval for a first-in-human trial of its BioJet oral adalimumab capsule.
Read more